finance
Biotalys Secures EUR 12.05 Million in Private Placement of New Shares with Existing Investors
Belgian agtech firm Biotalys announced it has obtained subscription commitments for EUR 12.05 million through a private placement of 7.88 million new shares. The funds will support biofungicide programs and platform development. Investors include current shareholders like Ackermans & van Haaren and Sofinnova Industrial Biotech I.
agfundernews.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Ghent, Belgium-based Biotalys announced on May 6, 2026, that it has obtained subscription commitments totaling EUR 12,050,000 through a private placement of new shares. 96% of the company's shares outstanding before the deal. Benzinga reported the issue price reflects a 40% discount to the volume-weighted average price of Biotalys's shares on Euronext Brussels from April 1 to April 30, 2026.
Investors in the placement are all current shareholders, including Ackermans & van Haaren NV, Agri Investment Fund BV, ASR Vermogensbeheer NV, Federale Participatie- en Investeringsmaatschappij NV, GIMV NV, PMV NV, Sofinnova Industrial Biotech I, and the Flemish Institute for Biotechnology VIB.
These participants have agreed to a three-month lock-up on both their new and existing shares following the placement's closing. The new shares will carry the same rights and benefits as existing ones, ranking pari passu in all respects.
Biotalys intends to allocate the proceeds to advance its biofungicide programs, EVOCA NG and BioFun-6, through further process development, field trials, and regulatory processes. 0 platform, while supporting the retention of key talent. 41, with issued and outstanding shares increasing from 37,568,645 to 45,444,456.
The board applied the procedure under article 7:97 of the Belgian Companies and Associations Code for the private placement. Payment and delivery of the new shares are scheduled for on or about May 20, 2026, after which they will be listed on Euronext Brussels. 96% dilution noted in the transaction details.
Simon Moroney, chairman of Biotalys, stated: 'On behalf of the board, I welcome this additional financing by our long-term reference shareholders. These investors support our view that there's an urgent and growing need for safe, efficacious and cost-competitive biocontrol solutions that can replace conventional chemistry.
